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four members of the 5-acyl-6,7-dihydrothieno[3,2-c]pyridine (termed
“RU-SKI”) class of inhibitors of Hedgehog acyltransferase, including
associated NMR spectra for ﬁnal compounds. RU-SKI compounds were
selected for synthesis based on their published high potencies against
the enzyme target. RU-SKI 41 (9a), RU-SKI 43 (9b), RU-SKI 101 (9c),
and RU-SKI 201 (9d) were proﬁled for activity in the related article
“Click chemistry armed enzyme linked immunosorbent assay to
measure palmitoylation by Hedgehog acyltransferase” (Lanyon-Hogg
et al., 2015) [1]. 1H NMR spectral data indicate different amide con-
formational ratios between the RU-SKI inhibitors, as has been
observed in other 5-acyl-6,7-dihydrothieno[3,2-c]pyridines. Thevier Inc. This is an open access article under the CC BY license
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T. Lanyon-Hogg et al. / Data in Brief 7 (2016) 257–281258synthetic and characterisation data supplied in the current article
provide validated access to the class of RU-SKI inhibitors.
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcation tableubject area Chemistry
ore speciﬁc sub-
ject areaOrganic Synthesisype of data Synthetic scheme, experimental procedures, physical data, NMR spectra
ow data was
acquiredNMR (Bruker AM-400 or AM-500). High resolution mass spectrometry
(AUTOSPEC P673 spectrometer). Microwave reactions (Biotage Initiator)ata format Analysed
xperimental
factorsN/Axperimental
featuresSynthesis performed using standard organic chemistry techniques without inert
atmosphere, unless otherwise stated.ata source location N/A
ata accessibility Data are available in this articleDValue of the data Validated synthetic route to substituted 5-acyl-6,7-dihydrothieno[3,2-c]pyridines.
 The synthesised compounds can be used as inhibitors of Hedgehog acyltransferase (Hhat), termed
“RU-SKI” inhibitors.
 Synthetic data provides route for development of other Hhat inhibitors based on this molecular
core with improved activity proﬁles.
 NMR spectral data demonstrate biologically active RU-SKI compounds possess variable amide
conformational preferences, which can be modulated.1. Data
This article describes the synthesis and characterisation of four 5-acyl-6,7-dihydrothieno[3,2-c]
pyridine (“RU-SKI”) inhibitors of Hedgehog acyltransferase (Hhat) which were employed in dose–
response analysis in the related article “Click-chemistry armed enzyme linked immunosorbent assay
to measure palmitoylation by Hedgehog acyltransferase” [1]. The RU-SKI inhibitors were identiﬁed
and developed by Resh and co-workers [2,3], and the compounds with the highest published
potencies against Hhat were selected for synthesis. RU-SKI 41 (9a), RU-SKI 43 (9b), RU-SKI 101 (9c)
and RU-SKI 201 (9d) were synthesised according to our previously reported synthetic strategy to
access the 5-acyl-6,7-dihydrothieno[3,2-c]pyridine core scaffold [4]. Inhibitors were analysed in our
Click Chemistry Armed Enzyme Linked Immunosorbent Assay, displaying low- and sub-micromolar
IC50 values against Hhat [1].
As demonstrated in our previous study of the 5-acyl-6,7-dihydrothieno[3,2-c]pyridine core [4], the
amide in the RU-SKI compounds also adopts two conformations (Fig. 1). The conformational pre-
ference is affected by non-covalent interactions between the amide carbonyl and neighbouring
Table 1
Amide conformational ratio data from RU-SKI inhibitors estimated by 1H NMR
spectroscopy measured at 400 MHz in CDCl3 (Figs. 2, 6, 10, and 14).
Compound Observed E:Z
RU-SKI 41 (9a) 1:1
RU-SKI 43 (9b) 4:6
RU-SKI 101 (9c) 2:8
RU-SKI 201 (9d) 7:3
N
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OR1
N
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O
R2R1
E-amide Z-amide
Fig. 1. E- and Z-amide conformations adopted by the 5-acyl-6,7-dihydrothieno[3,2-c]pyridine core of the RU-SKI compounds.
T. Lanyon-Hogg et al. / Data in Brief 7 (2016) 257–281 259substituents [4]. Altered conformational ratios are observed in the 1H NMR data of the RU-SKI
compounds (Table 1, Figs. 2,6,10 and 14). The synthetic, characterisation and conformational data of
compounds 9a–9d is reported here, along with NMR spectra of ﬁnal RU-SKI inhibitors.2. Experimental design, materials and methods
2.1. Materials
Materials and equipment were as previously described [4].
2.2. Abbreviations
EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide), PyBOP ((benzotriazol-1-yloxy)tripyrroli-
dinophosphonium hexaﬂuorophosphate), TEA (triethylamine), DIPEA (N,N-diisopropylethylamine),
DMF (dimethylformamide), DCM (dichloromethane), HOBt (hydroxybenzotriazole), TFA (tri-
ﬂuoroacetic acid), chex (cyclohexane).
2.3. General procedures
Synthesis of RU-SKI 41, 43, 101 and 201 followed our previously reported synthetic strategy
(Scheme 1) [4].
2.3.1. General procedure A (ethyl phenoxy acetate preparation)
2-Bromoethylacetate (0.66 mL, 5.99 mmol, 1 eq) was added dropwise to a solution of K2CO3
(1660 mg, 12.0 mmol, 2 eq) and phenol (5.99 mmol, 1 eq) in acetone (25 mL) and stirred at room
temperature overnight. The reaction mixture was concentrated in vacuo then dissolved in brine and
extracted with ethyl acetate. The combined organic layers were dried over Na2SO4 and the solvent
removed in vacuo. The phenyl ether was used without further puriﬁcation.
Scheme 1. General procedures. (A) K2CO3, acetone, room temperature, overnight. (B) NaOMe, MeOH, room temperature,
overnight. (C) PyBOP, DIPEA, DMF, room temperature, overnight. (D) POCl3, P2O5, toluene, 140 °C, microwave, 30 min. (E) POCl3,
P2O5, xylene, 85 °C, 2 h. (F) NaBH4, MeOH, room temperature, 1 h or overnight. G. DCM, 0 °C to room temperature, overnight.
(H) TEA, Boc2O, MeOH, 0 °C to 60 °C, 1 h. (I) 1 M LiBH4 in H2O, THF, room temperature, 1 h. (J) PyBOP, DIPEA, DCM, room
temperature, overnight. (K) EDC, HOBt, DMF, room temperature, overnight. (L) TFA: DCM (1:1), room temperature. (M) 4 M HCl
in dioxane, room temperature.
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Phenoxyethyl acetate (3.91 mmol, 1 eq) was dissolved in methanol (20 mL), and sodium meth-
oxide solution (0.5 M, 2.12 mL, 19.5 mmol, 5 eq) added dropwise to the reaction mixture. 2-(3-Thie-
nyl)ethylamine (0.47 mL, 508 mg, 3.91 mmol, 1 eq) was added dropwise and stirred overnight at
room temperature. The solvent was removed in vacuo and the resulting crude material was dissolved
in brine, extracted with ethyl acetate and the combined organic layers washed with water. The
organic layer was dried over Na2SO4, concentrated in vacuo and the crude residue puriﬁed by ﬂash
column chromatography.
2.3.3. General procedures C, D, E, F, and N
General procedures C, D, E, F, and N were performed as previously described [4].
2.3.4. General procedure G
General procedure G was performed as previously described [5].
2.3.5. General procedure H
General procedure G was performed as previously described [6].
2.3.6. General procedure I (ester hydrolysis of ethyl aminoacetate/preparation of ethyl amino acetic acid)
Boc-protected ethyl aminoacetate (0.15 mmol, 1 eq) was dissolved in THF (5 mL), lithium hydro-
xide (1 M solution, 0.4 mL, 0.40 mmol, 3.8 eq) added and the reaction stirred overnight at room
temperature. If necessary, more lithium hydroxide was added to the reaction mixture in order to drive
the reaction to completion. The reaction was acidiﬁed with concentrated hydrochloric acid (pH 2) and
extracted in ethyl acetate. The combined organic layers were dried over Na2SO4, concentrated in
vacuo, and puriﬁed by column chromatography or used without further puriﬁcation.
2.3.7. General procedure J (coupling of the side chain using PyBOP) (RU-SKI 41/43)
The amine obtained from general procedure F (0.11 mmol, 1 eq) was added to a solution of the acid
obtained from general procedure I (0.12 mmol, 1.1 eq), DIPEA (52 μL, 0.30 mmol, 2.75 eq) and PyBOP
(56 mg, 0.11 mmol, 1 eq) in DCM (5 mL) and the reaction stirred overnight at room temperature. The
reaction was quenched by addition of water and extracted in ethyl acetate. The combined organic
layers were washed with water and brine, dried over Na2SO4, concentrated in vacuo, and puriﬁed by
ﬂash column chromatography.
2.3.8. General procedure K (coupling of the side chain using EDC/HOBt) (RU-SKI 101/201)
The amine obtained from general procedure F (0.043 mmol, 1 eq) and the Boc-protected acetic
acid obtained from general procedure I (0.043 mmol, 1 eq) were dissolved in DMF (2 mL). HOBt
(5.8 mg, 0.043 mmol, 1 eq), DIPEA (15 μL, 0.086 mmol, 2 eq) and EDC (12.4 mg, 0.065 mmol, 1.5 eq)
were added to the reaction mixture and the reaction stirred overnight at room temperature. DCM was
added and the solution washed with aqueous LiCl (5% w/w) and brine. The organic layer was dried
over Na2SO4, concentrated in vacuo, and puriﬁed by ﬂash column chromatography.
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The amide obtained from general procedure J or K (0.049 mmol, 1 eq) was dissolved in 1:1 mixture
of DCM and TFA (5 mL). Afterwards, the solvent was removed in vacuo and the residual was neu-
tralised by saturated sodium hydrogen carbonate, extracted with DCM three times and dried over
MgSO4. The required amine was isolated using strong cation exchange resin and eluted with
ammonia (2 M) in methanol to recover the free amine, and puriﬁed by ﬂash column chromatography.
2.3.10. General procedure M (Boc deprotection by HCl in dioxane)
The amide obtained from general procedure J or K (0.18 mmol, 1 eq) was stirred in 4 M HCl-
Dioxane (5 mL) for 2 h at room temperature. The solvent was removed in vacuo and the residue
dissolved in ethyl acetate, washed with water and brine and dried over MgSO4. The required amine
was isolated using strong cation exchange resin and eluted with ammonia (2 M) in methanol to
recover the free amine, and puriﬁed by ﬂash column chromatography.
2.3.11. General procedure N (coupling of the side chain using acid chlorides)
The amine obtained from general procedure F (0.09 mmol, 1 eq) and TEA (25 μL, 18 mg, 0.18 mmol,
2 eq) were dissolved in dry DCM (1 mL). The corresponding acid chloride (0.11 mmol, 1.2 eq) was
added and the reaction mixture stirred at room temperature for 2 h. The solvent was removed in
vacuo, and the residue puriﬁed by ﬂash column chromatography.2.4. RU-SKI synthetic data
2.4.1. RU-SKI 41 synthetic data
2.4.1.1. Ethyl (p-chlorophenoxy)acetate (1a)
The ethyl (p-chlorophenoxy)acetate (1a) was obtained from 4-chlorophenol (0.59 mL, 770 mg,
5.99 mmol, 1 eq) and 2-bromoethylacetate (1 g, 5.99 mmol, 1 eq) using general procedure A as a
white solid (1.28 g, 5.87 mmol, 98%). 1H NMR (400 MHz, CDCl3) δ¼7.31–7.22 (m, 2H), 6.91–6.82 (m,
2H), 4.61 (s, 2H), 4.29 (q, 3J¼7.1 Hz, 2H), 1.31 (t, 3J¼7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ¼168.61,
156.46, 129.46, 126.70, 116.02, 65.63, 61.48, 14.15; IR υMAX (neat)/cm1: 2986 (CH3, -CH2-, alkyl),
1755.14 (C¼O stretch, ester), 1595.32, 1584.14, 1489.92, 1441.44, 1379.18, 1292.86, 1192.13, 1171.21,
1075.91, 1026.29, 1006.67, 929.80, 872.46, 719.30; HRMS (ESI, m/z) calcd. for C10H15NO3Clþ
[MþNH4]þ , 232.0740; found, 232.0738 [MþNH4]þ .
2.4.1.2. 2-(p-Chlorophenoxy)-1-[2-(2-thienyl)ethylamino]-1-ethanone (2a)
 
The amide (2a) was obtained from 2-(3-thienyl)ethylamine (0.47 mL, 500 mg, 3.91 mmol, 1 eq)
and ethyl (4-chlorophenoxy) acetate (850 mg, 3.91 mmol, 1 eq) using general procedure B as a white
solid (975 mg, 3.30 mmol, 73%). 1H NMR (400 MHz, CDCl3) δ¼7.31–7.26 (m, 2 H), 7.19 (dd, 3J¼5.1,
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3.10 (t, 3J¼6.7 Hz, 2 H); 13C NMR (101 MHz, CDCl3) δ¼167.79, 155.72, 140.71, 129.69, 127.09, 125.51,
124.14, 115.93, 67.60, 40.28, 29.83. IR υMAX (neat)/cm1: 3408.37, 3302.15, 3093.46, 3064.49, 2939.45,
2921.72, 2856.33 (CH3, -CH2-, alkyl), 1654.90 (C¼O stretch, amide), 1597.10, 1537.80, 1488.72, 1427.34,
1342.82, 1278.53, 1230.48, 1171.54, 1096.68, 1046.50, 1007.56, 826.76, 698.54, HRMS (ESI, m/z) calcd.
for C14H15NO2SClþ [MþH]þ , 296.0512; found, 296.0507 [MþH]þ .
2.4.1.3. (p-Chlorophenoxy)(1-thia-5-aza-4,5,6,7-tetrahydroinden-4-yl)methane (4a) (ring closured imine
3a)/(amine 4a)
The cyclic imine (3a) was obtained from 2-(4-chlorophenoxy)-1-[2-(2-thienyl)ethylamino]-1-etha-
none (2a) (348 mg, 1.18 mmol, 1 eq) using general procedure E as a brown oil (327 mg, 1.18 mmol, 100%).
The crude material was used without further puriﬁcation. 1H NMR (400 MHz, CDCl3) δ¼δ 7.18–7.11 (m,
3 H), 7.04–6.99 (m, 3 H), 5.56 (s, 2 H), 4.11 (t, 3J¼8.7 Hz, 2 H), 3.30 (t, 3J¼8.7 Hz, 2 H). The amine (4a) was
obtained from (4-chlorophenoxy)(1-thia-5-aza-6,7-dihydroinden-4-yl)methane (3a) (327 mg,
1.18 mmol, 1 eq) using general procedure F as yellow oil (181 mg, 0.65 mmol, 55%). 1H NMR (400 MHz,
CDCl3) δ¼7.28–7.23 (m, 2 H), 7.15 (d, 3J¼5.2 Hz, 1 H), 6.91–6.87 (m, 3 H), 4.42–4.37 (m, 1 H), 4.22 (dd,
2J¼9.1, 3J¼3.8 Hz, 1 H), 4.05 (t, 3J¼8.8 Hz, 1 H), 3.34 (dt, 2J¼12.0, 3J¼5.1 Hz, 1 H), 3.12 (ddd, 2J¼12.0,
3J¼7.2, 5.1 Hz, 1 H), 2.97–2.83 (m, 2 H).13C NMR (101 MHz, CDCl3) δ¼157.36, 136.14, 133.22, 129.38,
125.91, 124.52, 122.58, 115.87, 70.87, 54.08, 41.31, 26.03. IR υMAX (neat)/cm1: 3306.34 (-O-Ar, phenol),
3062.16, 2945.47, 2854.13 (-CH2-, alkyl), 1655.13 (N–H stretch, amine), 1596.82, 1583.67, 1537.80, 1488.44,
1368.75, 1313.41, 1286.47, 1171.28, 1139.99, 1099.45, 1087.64, 1057.58, 1007.72, 907.50, 854.11, 826.81,
805.72, 756.78, 699.55; HRMS (ESI, m/z), calcd. for C14H15NO2SClþ [MþH]þ , 296.0512; found, 296.0519
[MþH]þ .
2.4.1.4. Ethyl (allylamino)acetate (5a)
The ethyl aminoacetate (5a) was obtained from ethyl bromoacetate (0.66 mL, 1000 mg, 5.99 mmol,
1 eq) and allylamine (8.7 mL, 116.2 mmol, 19.4 eq) using general procedure G as a colourless oil (137 mg,
0.96 mmol, 15%). The crude material was used without further puriﬁcation. 1H NMR (400 MHz, CDCl3)
δ¼5.86 (ddt, 2J¼16.3, 3J ¼10.2, 6.1 Hz, 1 H), 5.21–5.08 (m, 2 H), 4.18 (q, 3J¼7.1 Hz, 2 H), 3.39 (s, 2 H),
3.26 (dt, 3J¼6.1, 4J ¼1.4 Hz, 2 H), 1.86 (s, N–H), 1.26 (t, 3J¼7.1 Hz, 3 H). 13C NMR (101 MHz, CDCl3)
δ¼172.51, 136.01, 116.99, 60.58, 51.64, 49.81, 14.67. IR υMAX (neat)/cm1: 2983.57, 2939.32 (CH3, -CH2-,
alkyl), 1747.22 (C¼O stretch, ester), 1647.13, 1465.64, 1421.11, 1380.02, 1216.37, 1025.87, 941.38, 854.71;
HRMS (ESI, m/z) calcd. for C7H14NO2þ [MþH]þ , 144.1025; found 144.1018 [MþH]þ .
2.4.1.5. Ethyl (N-allyl-N-tert-butoxycarbonylamino)acetate (6a)
The Boc protected ethyl aminoacetate (6a) was obtained from ethyl (allylamino)acetate (5a) (137 mg,
0.96 mmol, 1 eq) and di-tert-butyl dicarbonate (Boc2O) (209 mg, 0.96 mmol, 1 eq) using general procedure
T. Lanyon-Hogg et al. / Data in Brief 7 (2016) 257–281264H as white solid (95 mg, 0.39 mmol, 40%). The crude material was used without further puriﬁcation. 1H
NMR (400 MHz, CDCl3) δ¼5.76 (dd, 2J¼10.8, 3J¼5.9 Hz, 1 H), 5.17–5.07 (m, 2 H), 4.16 (qd, 3J¼7.1, 2.3 Hz,
2 H), 3.95–3.91 (m, 2 H), 3.86 (d, 2J¼5.7 Hz, 1 H), 3.80 (s, 1 H), 1.43 (s, 9 H) 1.25 (q, 3J¼6.9 Hz, 3 H); 13C
NMR (101 MHz, CDCl3) δ¼(C¼O too weak to be detected), 133.78, 133.69, 117.60, 116.80, 80.34, 60.96,
50.79, 50.34, 48.08, 47.74, 28.30, 28.25, 14.27, 14.16; IR υMAX (neat)/cm1: 2978.90, 2933.91 (CH3, -CH2-,
alkyl), 1751.62 (C¼O stretch, ester), 1697.69 (C¼O stretch, amide), 1434.77, 1396.05, 1366.58, 1246.43,
1192.20, 1165.13, 1143.63, 1028.45, 995.74, 971.72, 927.12, 887.08, 863.60, 775.82, 716.69; HRMS (ESI, m/z)
calcd. for C14H24N2O4Naþ [MþCH3CNþNa]þ , 307.1634; found, 307.1650 [MþCH3CNþNa]þ .2.4.1.6. (N-Allyl-N-tert-butoxycarbonylamino)acetic acid (7a)
The Boc protected aminoacetic acid (7a) was obtained from ethyl (N-allyl-N-tert-butox-
ycarbonylamino)acetate (6a) (37 mg, 0.15 mmol, 1 eq) using general procedure I as colourless oil
(32 mg, 0.15 mmol, 97%). 1H NMR (400 MHz, CDCl3) δ 5.78 (dt, 2J¼10.0, 3J¼4.5 Hz, 1 H), 5.22–5.13 (m,
2 H), 4.01–3.93 (m, 2 H), 3.91 (d, 2J¼5.8 Hz, 2 H), 1.47 (s, 9 H);13C NMR (101 MHz, CDCl3) δ¼175.15,
174.59, 155.94, 155.14, 133.50, 133.27, 117.91, 117.20, 80.92, 80.80, 50.89, 50.23, 47.62, 28.26, 28.22; IR
υMAX (neat)/cm1: 3077.35, 2923.95, 2796.96 (CH3, -CH2-, Alkyl), 1678.95 (C¼O stretch, carboxylic
acid), 1643.04 (C¼O stretch, amide), 1442.16, 1419.51, 1343.26, 1260.56, 1181.01, 1095.98, 993.81, 916.01;
HRMS (ESI, m/z) calcd. for C10H17O4NNaþ [MþNa]þ , 238.1050; found, 238.1043 [MþNa]þ .2.4.1.7. N-Allyl(2-{4-[(p-chlorophenoxy)methyl]-1-thia-5-aza-4,5,6,7-tetrahydroinden-5-yl}-2-oxoethyl)
amino 2,2-dimethylpropionate(8a)
The amide (8a) was obtained from (4-chlorophenoxy)(1-thia-5-aza-4,5,6,7-tetrahydroinden-4-yl)
methane (4a) (82 mg, 0.29 mmol, 1 eq) and (N-allyl-N-tert-butoxycarbonylamino)acetic acid (7a)
(69 mg, 0.32 mmol, 1.1 eq) using general procedure J as yellow oil (93 mg, 0.19 mmol, 67%). 1H NMR
(400 MHz, CDCl3) δ¼7.28–7.16 (m, 5 H), 7.15 (d, 3J¼4.7 Hz, 1 H), 6.94 (d, 3J¼5.2 Hz, 1 H), 6.85 (m, 5 H),
5.83 (s, 3 H), 5.31–4.94 (m, 5 H), 4.38 (s, 1 H), 4.25 (q, 3J¼8.4, 6.6 Hz, 3 H), 4.18–3.83 (m, 10 H), 3.62 (m,
1 H), 3.08–2.77 (m, 5 H), 1.42 (s, 18 H); 13C NMR (101 MHz, CDCl3) δ¼168.55, 167.90, 157.17, 156.73,
136.62, 134.08, 132.59, 130.43, 129.44, 129.33, 125.60, 124.82, 123.81, 123.30, 116.69, 116.04, 115.92,
115.74, 80.07, 69.56, 69.09, 60.39, 53.71, 50.86, 50.38, 50.27, 50.16, 47.87, 47.77, 40.92, 35.73, 28.33,
25.65, 24.76, 21.05, 14.20.
T. Lanyon-Hogg et al. / Data in Brief 7 (2016) 257–281 2652.4.1.8. 2-(Allylamino)-1-{4-[(p-chlorophenoxy)methyl]-1-thia-5-aza-4,5,6,7-tetrahydroinden-5-yl}-1-
ethanone (9a)
RU-SKI 41 (9a) was obtained from N-allyl(2-{4-[(p-chlorophenoxy)methyl]1-thia5-
aza4,5,6,7-tetrahydroinden5-yl}2-oxoethyl)amino 2,2-dimethylpropionate (8a) (86 mg,
0.18 mmol, 1 eq) using general procedure M as yellow oil (50 mg, 0.13 mmol, 73%). 1H NMR (400 MHz,
CDCl3, rotameric ratio E:Z 1:1) δ 7.28–7.21 (m, 5 H), 7.18 (d, 3J¼5.2 Hz, 1 H), 6.96 (d, 3J¼5.2 Hz, 1 H),
6.92 (d, 3J¼5.2 Hz, 1 H), 6.87–6.81 (m, 4 H), 5.99–5.86 (m, 3 H), 5.27–5.20 (m, 3 H), 5.14 (d,
3J¼10.3 Hz, 2 H), 5.06–5.00 (m, 1 H), 4.25 (dt, 3J¼7.2, 3.4 Hz, 2 H), 4.19–4.11 (m, 2 H), 4.05–3.98 (m,
1 H), 3.85 (d, 2J¼16.1 Hz, 1 H), 3.72–3.52 (m, 6 H), 3.51 (s, 3 H), 3.32 (m, 4 H), 3.04 (qd, 2J¼12.1,
3J¼4.4 Hz, 2 H), 2.95 (m, 3 H), 2.89–2.81 (m, 2 H); 13C NMR (101 MHz, CDCl3) δ¼171.08, 170.22, 157.14,
156.67, 136.64, 136.54, 136.39, 133.82, 132.57, 130.48, 129.52, 129.34, 126.45, 125.96, 125.56, 124.88,
123.90, 123.40, 116.52, 116.34, 115.91, 115.68, 69.59, 69.15, 53.64, 52.25, 52.20, 50.76, 50.05, 49.84,
40.61, 35.86, 25.64, 24.80; 13C NMR (DEPT) (101 MHz, CDCl3) δ¼136.53, 136.39, 129.52, 129.34, 125.56,
124.88, 123.91, 123.41, 116.53, 116.35, 115.90, 115.67, 69.59, 69.14, 53.64, 52.25, 52.20, 50.76, 50.05,
49.83, 40.61, 35.86, 25.64, 24.80; IR υMAX (neat)/cm1: 2905.66 (CH3, -CH2-, Alkyl), 1644.44 (C¼O
stretch, amide), 1491.88, 1427.41, 1284.32, 1242.08, 1212.27, 1170.89, 1092.26, 1046.83, 1006.02, 921.03,
825.66, 744.68, 710.72, 660.29; HRMS (ESI, m/z) calcd. for C19H21ClN2O2Sþ [MþH]þ , 377.1091; found,
377.1109 [MþH]þ .
2.4.2. RU-SKI 43 synthetic data
2.4.2.1. Ethyl (m-tolyloxy)acetate (1b)
The ethyl (m-tolyloxy)acetate (1b) was obtained from m-cresol (0.63mL, 0.65mg, 5.99 mmol, 1 eq) and
2-bromoethylacetate (0.66mL,1000mg, 5.99 mmol, 1 eq) using general procedure A as a white solid (1.09 g,
5.61mmol, 93%). 1H NMR (400MHz, CDCl3) δ¼7.17 (t, 3J¼7.9 Hz, 1 H), 6.81 (d, 3J¼7.5 Hz, 1 H), 6.74 (s, 1 H),
6.70 (dd, 2J¼8.2, 3J¼2.4 Hz, 1 H), 4.60 (s, 2 H), 4.27 (q, 3J¼7.1 Hz, 2 H), 2.32 (s, 3 H), 1.30 (t, 3J¼7.2 Hz, 3 H),
13C NMR (101MHz, CDCl3) δ¼169.52, 158.28, 140.11, 129.71, 123.02, 116.05, 111.85, 65.85, 61.76, 21.94, 21.50;
IR υMAX (neat)/cm1: 2984.65, 2924.90 (CH3, -CH2-, Alkyl), 2924.90, 1758.38, 1734.58 (C¼O, ester), 1586.99,
1489.76, 1442.80, 1378.32, 1275.60, 1261.07, 1200.37, 1156.26, 1088.71, 1029.60, 912.07, 857.19, 765.50, 750.32,
689.03; HRMS (ESI, m/z) calcd. for C11H15O3þ [MþH]þ , 195.1021; found, 195.1023 [MþH]þ .
2.4.2.2. 1-[2-(2-Thienyl)ethylamino]-2-(m-tolyloxy)-1-ethanone (2b)
The amide (2b) was obtained from 2-(3-thienyl)ethylamine (0.48 mL, 522mg, 4.08mmol, 1 eq) and ethyl
(m-tolyloxy)acetate (793 mg, 4.08mmol, 1 eq) using general procedure B as a white solid (853mg,
3.10mmol, 76%). 1H NMR (400MHz, CDCl3) δ¼7.19 (d, 3J¼7.8 Hz,1 H), 7.16 (ddd, 3J¼5.0, 3.0, 4J¼1.0 Hz,1 H),
6.94 (ddd, 3J¼7.5, 5.1, 4J¼3.4 Hz,1 H), 6.86–6.82 (m,1 H), 6.79–6.76 (m,1 H), 6.71–6.65 (m, 2 H), 4.47 (s, 2 H),
3.62 (q, 3J¼6.6 Hz, 2 H), 3.07 (t, 3J¼6.7 Hz, 2 H), 2.34 (s, 3 H); 13C NMR (101MHz, CDCl3) δ¼168.36, 157.19,
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cm1: 3103.09 (-O-Ar, br, phenol), 3046.00, 2922.20, 2860.65 (CH3, -CH2-, alkyl), 1663.53 (C¼O stretch,
amide), 1586.94, 1532.30, 1488.90, 1437.13, 1365.63, 1258.27, 1157.44, 1067.43, 920.48, 849.56, 824.35, 765.74,
750.20, 689.79; HRMS (ESI, m/z) calcd. for C15H18NO2Sþ [MþH]þ , 276.1058; found, 276.1071 [MþH]þ .
2.4.2.3. (1-Thia-5-aza-4,5,6,7-tetrahydroinden-4-yl)(m-tolyloxy)methane (4b) (ring closured imine 3b)/
(amine 4b)
The cyclic imine (1-thia-5-aza-6,7-dihydroinden-4-yl)(m-tolyloxy)methane (3b) was obtained from 1-
[2-(2-thienyl)ethylamino]-2-(m-tolyloxy)-1-ethanone (2b) (807 mg, 2.93 mmol, 1 eq) using general proce-
dure E as an orange oil (476 mg, 1.85 mmol, 63%). The crude material was used without further puriﬁcation.
1H NMR (400MHz, CDCl3) δ¼7.33–7.25 (m, 1 H), 7.23–7.05 (m, 2 H), 7.03–6.93 (m, 1 H), 6.83 (s, 1 H), 6.83–
6.75 (m, 1 H), 4.98 (s, 2 H), 3.91 (ddt, 2J¼9.7, 3J¼7.3, 1.2 Hz, 2 H), 2.92 (m, 2 H), 2.30 (s, 3 H). The cyclic
amine (4b) was obtained from (1-thia-5-aza-6,7-dihydroinden-4-yl)(m-tolyloxy)methane (3b) (476 mg,
1.85 mmol, 1 eq) using general procedure F as a yellow solid (235 mg, 0.91mmol, 49%). 1H NMR (400MHz,
CDCl3) δ¼7.20 (t, 3J¼7.9 Hz, 1 H), 7.14 (d, 3J¼5.2 Hz, 1 H), 6.92 (d, 3J¼5.2 Hz, 1 H), 6.81 (t, 3J¼6.5 Hz, 3 H),
4.43–4.38 (m, 1 H), 4.24 (dd, 2J¼9.2, 3J¼3.8 Hz, 1 H), 4.11–4.06 (m, 1 H), 3.34 (dt, 2J¼12.0, 3J¼5.2 Hz, 1 H),
3.12 (ddd, 2J¼12.1, 3J¼6.9, 5.2 Hz, 1 H), 2.90 (tt, 2J¼10.7, 3J¼5.2 Hz, 2 H), 2.36 (s, 3 H), 2.31 (s, 1 H, N–H); 13C
NMR (101MHz, CDCl3) δ¼158.74, 139.55, 136.00, 133.55, 129.23, 124.67, 122.42, 121.84, 115.44, 111.48, 70.30,
54.20, 41.23, 26.07, 21.54; IR υMAX (neat)/cm1 2919.94, 2865.60, 2837.79 (alkyl, CH3, -CH2-), 1600.89 (N–H
stretch, amine), 1584.04, 1488.99, 1466.59, 1433.15, 1382.23, 1359.82, 1326.95, 1311.57, 1290.14, 1259.12,
1170.61,1156.70,1132.10,1047.23,1032.89, 994.75, 879.52, 827.82, 769.24, 752.00, 711.74, 688.35; HRMS (ESI,
m/z) calcd. for C15H18NOSþ [MþH]þ , 260.1109; found, 260.1112 [MþH]þ .
2.4.2.4. Ethyl (2-methylbutylamino)acetate (5b)
The ethyl aminoacetate (5b) was obtained from ethyl bromoacetate (166 μL 250 mg, 1.50 mmol,
1 eq) and 2-methyl butylamine (3.3 mL, 2.53 g, 29.04 mmol, 1 eq) using general procedure G. The
crude material was puriﬁed by Isolera (SiO2; EtOAc:Hexane:TEA-12:88:1) and the expected com-
pound was recovered as colourless oil (152 mg, 0.88 mmol, 58%).1H NMR (400 MHz, CDCl3) δ¼4.16 (q,
3J¼7.1 Hz, 2 H), 3.35 (s, 2 H), 2.59 (dd, 2J¼12.6, 3J¼5.5 Hz, 1 H), 2.52–2.46 (dd, 2J¼11.2, 3J¼7.1 Hz 1 H),
2.35 (dd, 2J¼11.2, 3J¼7.1 Hz, 1 H), 1.53–1.32 (m, 2 H), 1.25 (t, 3J¼7.1 Hz, 3 H), 0.91–0.82 (m, 6 H); 13C
NMR (101 MHz, CDCl3) δ¼172.62, 60.65, 55.70, 51.24, 34.95, 27.32, 17.56, 11.23; HRMS (ESI, m/z) calcd.
for C9H20NO2þ [MþH]þ , 174.1494; found, 174.1497 [MþH]þ .
2.4.2.5. Ethyl [N-tert-butoxycarbonyl(2-methylbutyl)amino]acetate (6b)
The Boc protected ethyl aminoacetate (6b) was obtained from ethyl (2-methylbutylamino)acetate
(5b) (152 mg, 0.88 mmol, 1 eq) and di-tert-butyl dicarbonate (Boc2O) (427 mg, 1.955 mmol, 2.2 eq)
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the expected compound was obtained as white solid (139 mg, 0.51 mmol, 57%). 1H NMR (400 MHz,
CDCl3) δ 4.21 (qd, 3J¼7.1, 3.1 Hz, 2 H), 4.02–3.90 (m, 1 H), 3.86 (s, 1 H), 3.20 (dd, 2J¼14.2, 3J¼6.7 Hz,
1 H), 3.08 (ddd, 2J¼32.8, 3J¼14.2, 8.0 Hz, 1 H), 1.62 (dd, 2J¼13.7, 3J¼5.7 Hz, 1 H), 1.47 (s, 9 H), 1.41 (d,
3J¼6.3 Hz, 1 H), 1.30 (q, 3J¼7.2 Hz, 3 H), 1.13 (dt, 2J¼13.8, 3J¼7.3 Hz, 1 H), 0.95–0.87 (m, 6 H); 13C NMR
(101 MHz, CDCl3) δ¼170.25, 170.11, 156.15, 155.57, 80.01, 79.92, 60.93, 54.39, 54.35, 49.99, 49.32,
34.26, 33.97, 28.35, 28.25, 27.41, 26.89, 17.03, 16.81, 14.26, 14.15, 11.31; IR υMAX (neat)/cm1: 2966.24,
2932.72, 2877.14 (CH3, -CH2-, alkyl), 1753.57 (C¼O stretch, ester), 1695.10 (C¼O stretch, amide),
1456.93, 1403.46, 1365.89, 1245.03, 1192.65, 1174.47, 1145.09, 1096.17, 1029.26, 969.04, 930.01, 886.08,
863.78, 775.68; HRMS (ESI, m/z): calcd. for C16H30N2O4Naþ [MþCH3CNþNa]þ , 337.2103; found,
337.2112 [MþCH3CNþNa]þ .
2.4.2.6. [N-tert-Butoxycarbonyl(2-methylbutyl)amino]acetic acid (7b)
The Boc protected aminoacetic acid (7b) was obtained from ethyl [N-tert-butoxycarbonyl(2-
methylbutyl)amino]acetate (6b) (51 mg, 0.19 mmol, 1 eq) using general procedure I as colourless oil
(44 mg, 0.18 mmol, 95%). 1H NMR (400 MHz, CDCl3) δ¼4.00 (d, 3J¼4.0 Hz, 1 H), 3.92 (s, 1 H), 3.21 (dd,
2J¼14.3, 3J¼6.6 Hz, 1 H), 3.16–3.02 (m, 1 H), 1.64 (s, 1 H), 1.47 (s, 9 H), 1.42–1.25 (m, 1 H), 1.13 (dt,
2J¼14.5, 3J¼7.6 Hz, 1 H), 0.91 (m, 6 H); 13C NMR (101 MHz, CDCl3) δ¼175.72, 174.65, 156.70, 155.49,
80.80, 80.38, 77.34, 77.23, 77.02, 76.88, 76.71, 54.62, 54.23, 49.50, 34.19, 33.94, 28.32, 28.23, 26.86,
16.96, 16.80, 11.29; IR υMAX (neat)/cm1: 2965.36, 2933.32, 2877.19 (Alkyl, CH3, -CH2-), 1695.08 (br,
C¼O stretch merged together, carboxylic acid and carbamate), 1461.49, 1423.92, 1403.69, 1366.79,
1246.53, 1147.12, 1098.08, 969.73, 927.38, 871.21, 766.79; HRMS (ESI, m/z) calcd. for C14H26N2O4Naþ
[MþCH3CNþNa]þ , 309.1785; found, 309.1806 [MþCH3CNþNa]þ .
2.4.2.7. (2-Oxo2-{4-[(m-tolyloxy)methyl]1-thia5-aza4,5,6,7-tetrahydroinden5-yl}ethyl)(2-
methylbutyl)amino 2,2-dimethylpropionate (8b)
The amide (8b) was obtained from (1-thia5-aza4,5,6,7-tetrahydroinden4-yl)(m-tolyloxy)
methane (4b) (31 mg, 0.12 mmol, 1 eq) and (7b) [N-tert-butoxycarbonyl(2-methylbutyl)amino]acetic
acid (32.3 mg, 0.13 mmol, 1.1 eq) using general procedure J as yellow oil (21 mg, 0.045 mmol, 37%). 1H
NMR (400 MHz, CDCl3) δ 7.23–7.13 (m, 4 H), 6.97 (d, 3J¼5.3 Hz, 1 H), 6.91 (dd, 3J¼15.3, 5.2 Hz, 1 H),
6.82 (t, 3J¼6.2 Hz, 1 H), 6.77 (d, 3J¼6.8 Hz, 2 H), 6.70 (d, 3J¼8.0 Hz, 3 H), 5.31–5.22 (m, 1 H), 4.99 (dt,
2J¼11.6, 3J¼5.5 Hz, 1 H), 4.57–4.43 (m, 1 H), 4.37–4.23 (m, 3 H), 4.14 (m, 3 H), 3.69 (dd, 2J¼17.9,
3J¼7.2 Hz, 1 H), 3.35 (dtd, 2J¼42.4, 3J¼14.3, 7.6 Hz, 3 H), 3.23–2.76 (m, 6 H), 2.33 (s, 6 H), 1.54–1.25
(m, 25 H), 1.20–1.05 (m, 2 H), 0.92 (dp, 3J¼9.8, 3.1 Hz, 12 H); 13C NMR (101 MHz, CDCl3) δ¼171.14,
167.83, 158.59, 158.09, 156.42, 139.71, 139.45, 136.59, 133.76, 132.90, 130.68, 129.32, 129.15, 125.68,
124.90, 123.69, 123.10, 122.25, 121.77, 115.52, 115.38, 111.26, 111.04, 110.95, 79.99, 79.67, 69.31, 69.21,
68.93, 68.66, 54.29, 54.13, 53.73, 51.10, 49.27, 48.83, 40.97, 35.62, 34.05, 33.83, 28.40, 28.26, 27.00,
25.69, 24.80, 21.46, 17.12, 16.90, 11.45, 11.34; IR υMAX (neat)/cm1: 2962.99, 2926.50, 2874.48 (CH3,
-CH2-, alkyl), 1694.23 (C¼O stretch, carbamate), 1661.69 (C¼O stretch, amide), 1602.85, 1585.14,
1460.59, 1433.04, 1364.90, 1260.21, 1246.48, 1208.04, 1156.84, 1095.12, 1053.60, 968.15, 927.76, 878.13,
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[MþH]þ .
2.4.2.8. 2-(2-Methylbutylamino)-1-{4-[(m-tolyloxy)methyl]-1-thia-5-aza-4,5,6,7-tetrahydroinden-5-yl}-
1-ethanone (9b)
RU-SKI 43 (9b) was obtained from N-allyl(2-{4-[(p-chlorophenoxy)methyl]-1-thia-5-aza-4,5,6,7-
tetrahydroinden-5-yl}-2-oxoethyl)amino 2,2-dimethylpropionate (8b) (15.8 mg, 0.033 mmol, 1 eq)
using general procedure L as yellow oil (8.1 mg, 0.021 mmol, 62%). 1H NMR (400 MHz, CDCl3, rota-
meric ratio E:Z 4:6) δ¼7.24–7.13 (m, 4 H), 6.98 (d, 3J¼5.2 Hz, 1 H), 6.93 (d, 3J¼5.2 Hz, 1 H), 6.82 (d,
3J¼7.5 Hz, 1 H), 6.77 (d, 3J¼7.6 Hz, 1 H), 6.73–6.67 (m, 4 H), 5.89 (t, 3J¼4.7 Hz, 1 H), 5.27 (dd, 2J¼8.8,
3J¼4.1 Hz, 1 H), 5.01 (dd, 2J¼12.8, 3J¼4.5 Hz, 1 H), 4.31–4.24 (m, 2 H), 4.22–4.12 (m, 2 H), 4.06–4.00
(m, 1 H), 3.89 (dd, 2J¼16.0, 3J¼2.0 Hz, 1 H), 3.73–3.49 (m, 4 H), 3.07 (td, 2J¼12.2, 3J¼3.9 Hz, 1 H), 2.96
(dq, 2J¼16.8, 3J¼6.5, 5.7 Hz, 2 H), 2.87–2.81 (m, 1 H), 2.58 (tdd, 3J¼9.7, 6.1, 4J¼3.8 Hz, 2 H), 2.51–2.41
(m, 2 H), 2.34 (s, 3 H), 2.32 (s, 3 H), 1.54 (dddd, 2J¼40.6, 3J¼19.2, 12.0, 5.2 Hz, 4 H), 1.19 (dtd, 2J¼14.8,
3J¼7.4, 4.0 Hz, 2 H), 1.00–0.89 (m, 11 H); 13C NMR (101 MHz, CDCl3) δ¼170.97, 170.18, 158.55, 158.05,
139.75, 139.47, 136.47, 133.69, 132.85, 130.76, 129.34, 129.15, 125.64, 124.97, 123.77, 123.19, 122.29,
121.81, 115.50, 115.28, 111.28, 111.04, 69.22, 68.66, 56.31, 53.73, 51.52, 50.96, 50.91, 40.68, 35.81, 35.02,
34.91, 27.43, 27.35, 25.65, 24.81, 21.46, 17.65, 17.57, 11.29, 11.21; HRMS (ESI, m/z) calcd. for
C22H31N2O2Sþ [MþH]þ , 387.2101; found, 387.2109 [MþH]þ .
2.4.3. RU-SKI 101 Synthetic Data
2.4.3.1. 4-(m-Tolyl)-1-thia-5-aza-4,5,6,7-tetrahydroindene (4c)
The amine was synthesised as previously described [4].
2.4.3.2. 2-(2-Methylbutylamino)-1-[4-(m-tolyl)-1-thia-5-aza-4,5,6,7-tetrahydroinden-5-yl]-1-ethanone
(8c)
The amide (8c) was obtained from 4-(m-tolyl)-1-thia-5-aza-4,5,6,7-tetrahydroindene (4c) (28 mg,
0.12 mmol, 1 eq) and [N-tert-butoxycarbonyl(2-methylbutyl)amino]acetic acid (7b) (30 mg, 0.12 mmol,
1 eq) using general procedure K as a yellow oil (35 mg, 0.08 mmol, 64%). Rf 0.14 (SiO2; EtOAc:Hex, 1:9). 1H
NMR (400 MHz, CDCl3) δ 7.17 (m, 3 H), 7.11 (d, 3J¼7.4 Hz, 1 H), 7.05 (d, 3J¼7.6 Hz, 1 H), 6.84 (s, 1 H), 6.71
(s, 1 H), 4.33 (t, 3J¼14.2 Hz, 1 H), 4.10–3.72 (m, 2 H), 3.39 (s, 1 H), 3.28–2.79 (m, 4 H), 2.33 (s, 3 H), 1.68 (s,
1 H), 1.49 (s, 6 H), 1.35 (s, 3 H), 1.28 (s, 1 H), 1.10 (s, 1 H), 0.96–0.74 (m, 6 H).13 C NMR, HRMS (ESI, m/z)
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(9c)
RU-SKI 101 (9c) was obtained from 2-(2-methylbutylamino)-1-[4-(m-tolyl)-1-thia-5-aza-4,5,6,7-
tetrahydroinden-5-yl]-1-ethanone (8c) (44 mg, 0.10 mmol, 1 eq) using general procedure L as yellow
oil (18 mg, 0.05 mmol, 52%). 1H NMR (400 MHz, CDCl3, rotameric ratio E:Z 2 :8) δ¼ 7.27–6.98 (m,
7 H), 6.87 (s, 1 H), 6.77 (d, 3J¼5.3 Hz, 1 H), 6.72 (d, 3J¼5.2 Hz, 1 H), 5.90 (s, 1 H), 4.89 (d, 3J¼8.9 Hz,
1 H), 3.81 (dd, 2J¼14.1, 3J¼5.0 Hz, 1 H), 3.53 (qd, 2J¼15.8, 3J¼4.4 Hz, 2 H), 3.37 (td, 2J¼14.1, 3J¼4.3 Hz,
1 H), 3.04 (ddd, 2J¼16.8, 3J¼11.4, 5.6 Hz, 2 H), 2.97–2.83 (m, 2 H), 2.58 (dt, 2J¼11.2, 3J¼5.6 Hz, 1 H),
2.45 (ddd, 3J¼10.9, 7.2, 4J¼2.5 Hz, 2 H), 2.33 (s, 4 H), 2.27–2.20 (m, N–H), 1.59 (dp, 2J¼13.3, 3J¼6.6 Hz,
1 H), 1.47 (dq, 2J¼13.0, 3J¼6.5, 5.6 Hz, 2 H), 1.19 (dt, 2J¼14.6, 3J¼6.5 Hz, 2 H), 0.93 (dt, 2J¼14.8,
3J¼7.0 Hz, 9 H); 13C NMR (101 MHz, CDCl3) δ¼169.20, 144.73, 140.82, 138.15, 134.12, 134.00, 133.67,
129.35, 128.82, 128.62, 128.18, 126.63, 126.07, 125.77, 125.68, 124.50, 123.36, 123.28, 56.32, 54.02, 51.21,
38.51, 34.99, 34.96, 27.46, 27.36, 25.74, 21.48, 17.65, 11.34, 11.29; IR υMAX (neat)/cm1: 2958.22,
2922.15, 2874.72 (CH3, -CH2-, alkyl), 1646.21 (C¼O, amide), 1461.28, 1424.10, 1379.20, 1332.27,
1289.10, 1208.03, 1172.73, 1152.07, 1044.79, 892.05, 837.88, 810.68, 767.27, 736.91, 708.37; HRMS (ESI,
m/z) calcd. for C21H29N2OSþ [MþH]þ , 357.1995; found, 357.2019 [MþH]þ .2.5. RU-SKI 201 synthetic data
2.5.1. (6-Methyl-2-pyridyl)[2-(2-thienyl)ethylamino]formaldehyde (2d)
The amide (2d) was obtained from 2-(3-thienyl)ethylamine (390 uL, 424 mg, 3.31 mmol, 1 eq) and
6-methylpyridine-2-carboxylic acid (500 mg, 3.65 mmol, 1.1 eq) using general procedure C as a col-
ourless oil (650 mg, 2.64 mmol, 72%). 1H NMR (400 MHz, CDCl3) δ¼8.35 (s, 1 H, N–H), 8.02 (d,
3J¼7.7 Hz, 1 H), 7.73 (t, 3J¼7.7 Hz, 1 H), 7.28 (d, 3J¼7.4 Hz, 1 H), 7.19 (d, 3J¼5.1 Hz, 1 H), 7.00–6.96 (m,
1 H), 6.92 (d, 3J¼3.2 Hz, 1 H), 3.77 (q, 3J¼6.8 Hz, 2 H), 3.19 (t, 3J¼7.0 Hz, 2 H), 2.56 (s, 3 H); 13C NMR
(101 MHz, CDCl3) δ¼164.55, 157.12, 149.11, 141.35, 137.46, 127.01, 125.87, 125.33, 123.85, 119.21, 40.86,
30.14, 24.25; IR υMAX (neat)/cm1: 3256.7 (C–H stretch, Ar–H), 2920.3, 2902.4, 2824, 2806 (CH3, -CH2-
, alkyl), 1667.66 (C¼O stretch, amide), 1593.76, 1518.38, 1490.74, 1451.76, 1330.58, 1278.30, 1210.09,
1198.23, 1112.15, 1082.07, 1071.68.1052.13, 1025.33, 984.79, 931.22, 915.08, 901.76, 867.48, 853.24,
840.63, 823.83, 759.51, 726.94, 700.82, 686.66; HRMS (ESI, m/z) calcd. for C13H15N2OSþ [MþH]þ ,
247.0905; found, 247.0916 [MþH]þ .
2.5.2. 4-(6-Methyl-2-pyridyl)-1-thia-5-aza-4,5,6,7-tetrahydroindene (4d) (ring closured imine 3d)/
(amine 4d)
The cyclic imine (3d) was obtained from (6-methyl-2-pyridyl)[2-(2-thienyl)ethylamino]for-
maldehyde (2d) (610 mg, 4.76 mmol, 1 eq) using general procedure E as a brown oil (478 mg,
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δ¼8.03 (d, 3J¼7.6 Hz, 1 H), 7.82 (d, 3J¼7.7 Hz, 1 H), 7.58 (d, 3J¼5.2 Hz, 1 H), 7.02 (d, 3J¼5.9 Hz, 1 H),
6.99 (dd, 3J¼5.1, 3.4 Hz, 1 H), 4.08–4.03 (m, 2 H), 3.03–2.96 (m, 2 H), 2.29 (s, 3 H); The amine (4d) was
obtained from 4-(6-methyl-2-pyridyl)-1-thia-5-aza-6,7-dihydroindene (3d) (468 mg, 2.05 mmol,
1 eq) using general procedure G as brown oil (281 mg, 1.22 mmol, 49% over two steps). 1H NMR
(400 MHz, CDCl3) δ¼7.52 (t, 3J¼7.7 Hz, 1 H), 7.05 (dd, 3J¼6.4, 3.2 Hz, 3 H), 6.98 (d, 3J¼7.7 Hz, 1 H),
6.62 (d, 3J¼5.2 Hz, 1 H), 5.15 (s, 1 H), 3.28 (dt, 2J¼12.2, 3J¼5.1 Hz, 1 H), 3.14 (ddd, 2J¼12.3, 3J¼7.6,
5.1 Hz, 1 H), 3.02–2.86 (m, 2 H), 2.57 (s, 3 H); 13C NMR (101 MHz, CDCl3) δ¼161.30, 158.08, 136.70,
135.27, 135.18, 126.13, 122.00, 121.95, 119.29, 60.83, 41.90, 25.88, 24.51; IR υMAX (neat)/cm1: 3289.25,
3044.04 (C–H stretch, Ar–H), 2923.00 (CH3, -CH2-, alkyl), 1592.05 (N–H stretch, amine), 1574.69 (N–H
stretch, amine), 1442.07, 1372.97, 1260.56, 1208.46, 1158.68, 1146.21, 1123.21, 1090.07, 1032.98, 991.98,
934.93, 873.05, 851.80, 797.99, 766.03, 739.69, 712.11; HRMS (ESI, m/z) calcd. for C13H15N2Sþ
[MþH]þ , 231.0950; found, 231.0959 [MþH]þ .
2.5.3. {2-[4-(6-Methyl-2-pyridyl)-1-thia-5-aza-4,5,6,7-tetrahydroinden-5-yl]-2-oxoethyl}(2-methylbu-
tyl)amino 2,2-dimethylpropionate (8d)
The amide (8d) was obtained from 4-(6-methyl-2-pyridyl)-1-thia-5-aza-4,5,6,7-tetrahydroindene
(4d) (5.5 mg, 0.024 mmol, 1 eq) and [N-tert-Butoxycarbonyl(2-methylbutyl)amino]acetic acid (7b)
(5.8 mg, 0.024 mmol, 1 eq) using general procedure K as yellow oil (9.8 mg, 0.021 mmol, 90%),1H NMR
(400 MHz, CDCl3) δ¼7.52 (q, 3J¼7.0, 6.4 Hz, 4 H), 7.16 (d, 2J¼4.3 Hz, 3 H), 7.09 (t, 3J¼6.6 Hz, 4 H), 6.89
(dd, 3J¼24.5, 5.1 Hz, 4 H), 6.58 (s, 1 H), 6.01 (d, 2J¼17.2 Hz, 2 H), 4.94 (dd, 2J¼24.0, 3J¼9.4 Hz, 1 H),
4.74–4.53 (m, 2 H), 4.09–4.02 (m, 1 H), 3.45 (dd, 2J¼14.9, 3J¼7.2 Hz, 1 H), 3.33–3.17 (m, 1 H), 3.15–3.09
(m, 1 H), 3.06–2.80 (m, 6 H), 2.58 (s, 5 H), 1.48 (s, 15 H), 1.11 (ddd, 2J¼18.7, 3J ¼13.3, 6.1 Hz, 4 H), 0.90
(m, 10 H).
2.5.4. 2-(2-Methylbutylamino)-1-[4-(6-methyl-2-pyridyl)-1-thia-5-aza-4,5,6,7-tetrahydroinden-5-yl]-1-
ethanone (9d)
RU-SKI 201 (9d) was obtained from {2-[4-(6-methyl-2-pyridyl)-1-thia-5-aza-4,5,6,7-tetra-
hydroinden-5-yl]-2-oxoethyl}(2-methylbutyl)amino 2,2-dimethylpropionate (8d) (7.7 mg,
0.017 mmol, 1 eq) using general procedure L as yellow oil (1.9 mg, 0.0053 mmol, 31%). 1H NMR
(400 MHz, CDCl3, rotameric ratio E:Z 7:3) δ¼7.53–7.47 (m, 2 H), 7.15 (t, 3J¼6.9 Hz, 1 H), 7.07 (t,
3J¼7.5 Hz, 1 H), 6.99 (d, 3J¼7.4 Hz, 1 H), 6.88 (d, 3J¼5.2 Hz, 1 H), 6.85 (d, 3J¼5.1 Hz, 1 H), 6.79 (d,
3J¼7.7 Hz, 1 H), 6.56 (s, 1 H), 5.96 (s, 1 H), 4.96–4.87 (m, 1 H), 4.21 (d, 2J¼16.3 Hz, 1 H), 4.09–3.95 (m,
1 H), 3.83 (dd, 2J¼16.3, 3J¼4.0 Hz, 1 H), 3.60 (qd, 2J¼16.3, 3J¼15.9, 5.3 Hz, 1 H), 3.06–2.83 (m, 4 H),
2.70–2.39 (m, 8 H), 1.70–1.39 (m, 3 H), 1.17 (dddd, 2J¼23.2, 3J¼20.5, 15.5, 7.6 Hz, 2 H), 0.97–0.85 (m,
10 H); 13C NMR (101 MHz, CDCl3) δ¼170.22, 169.70, 159.07, 158.88, 158.60, 137.06, 136.77, 135.78,
134.25, 133.06, 132.13, 126.73, 126.35, 123.72, 123.00, 122.67, 122.07, 119.00, 118.53, 58.90, 56.69, 56.43,
T. Lanyon-Hogg et al. / Data in Brief 7 (2016) 257–281 27156.19, 51.41, 50.97, 40.85, 37.04, 35.07, 34.55, 31.09, 27.48, 27.39, 25.78, 25.00, 24.82, 24.64, 17.75, 17.60,
11.35, 11.29; IR υMAX (neat)/cm1: 3401.51 (br, C–H stretch, Ar–H), 3004.68, 2920.3 (CH3, -CH2-, alkyl),
1660.01 (C¼O stretch, amide), 1436.89, 1406.87, 1314.26, 1261.75, 1015.25, 951.75, 900.43, 702.76,
670.50; HRMS (ESI, m/z): calcd. for C20H28N3OSþ [MþH]þ , 358.1963; found, 358.1953 [MþH]þ .2.6. NMR spectra
2.6.1. RU-SKI 41 NMR spectral data
See Figs. 2–5.R
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Fig. 2. 1H NMR (400 MHz, CDCl3) of RU-SKI 41 (9a).
Fig. 3. 13C NMR (101 MHz, CDCl3) of RU-SKI 41 (9a).
Fig. 4. 2D COSY (400 MHz, CDCl3) of RU-SKI 41 (9a).
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Fig. 5. 2D HSQC (400 MHz, CDCl3) of RU-SKI 41 (9a).
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See Figs. 6–9.R
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Fig. 6. 1H NMR (400 MHz, CDCl3) of RU-SKI 43 (9b).
Fig. 7. 13C NMR (101 MHz, CDCl3) of RU-SKI 43 (9b).
Fig. 8. 2D COSY (400 MHz, CDCl3) of RU-SKI 43 (9b).
T. Lanyon-Hogg et al. / Data in Brief 7 (2016) 257–281 275
Fig. 9. 2D HSQC NMR (400 MHz, CDCl3) of RU-SKI 43 (9b).
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See Figs. 10–13.R
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Fig. 10. 1H NMR (400 MHz, CDCl3) of RU-SKI 101 (9c).
Fig. 11. 13C NMR (101 MHz, CDCl3) of RU-SKI 101 (9c).
Fig. 12. 2D COSY (400 MHz, CDCl3) of RU-SKI 101 (9c).
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Fig. 13. 2D HSQC (400 MHz, CDCl3) of RU-SKI 101 (9c).
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See Figs. 14–17.R
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Fig. 14. 1H NMR (400 MHz, CDCl3) of RU-SKI 201 (9d).
Fig. 15. 13C NMR (101 MHz, CDCl3) of RU-SKI 201 (9d).
Fig. 16. 2D COSY (400 MHz, CDCl3) of RU-SKI 201 (9d).
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Fig. 17. 2D HSQC (400 MHz, CDCl3) of RU-SKI 201 (9d).
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